Treatment with anti-ErbB2 antibody combinations
US7501122B2 · kind B2 · utility
40Cited by
101References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 9, 2005 |
| Grant date | Mar 10, 2009 |
| Priority date | — |
| Expiry date | Mar 20, 2026 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/801
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application describes methods for treating ErbB-expressing cancer with anti-ErbB2 antibody combinations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.